R1 RCM — Q2 2020 Earnings Presentation
13 slides from R1 RCM's earnings presentation, Aug 4, 2020
Slide 1: Second Quarter 2020 Results Conference Call
Exhibit 99.2 Second Quarter 2020 Results Conference Call August 4, 2020
Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures
Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not pa
Slide 3: Q2 Financial Highlights and 2020 Outlook
Q2 Financial Highlights and 2020 Outlook Second Quarter 2020 Financial Highlights ▪ Revenue of $314.7 million, up $19.7 million and 6.7% compared to the same period last year ▪ GAAP net income of $15.1 million, compared to net loss of $5.2 million in the same period last year ▪ Adjusted EBITDA of $6
Slide 4: COVID-19 Update and Volume Trends
COVID-19 Update and Volume Trends Health and Safety of Workforce ▪ Provide protective equipment for frontline employees and ensure a safe environment by increasing work-from-home ▪ Continue to serve our customers without any disruption Actions we have taken to support our Customers ▪ Faster conversi
Slide 5: Deployment Update
Deployment Update Penn State Health ▪ Initiated onboarding activities in May, proceeding on schedule under a virtual model ▪ Expect onboarding to conclude in the first quarter of 2021 Rush University System for Health (RUSH) ▪ Progressing on schedule, also under a virtual model ▪ Evolving COVID-19 r
Slide 6: Commercial Update
Commercial Update End-to-End and Modular Pipeline Up Sequentially ▪ Increase in RFP activity, as well interest from >$5 billion NPR health systems ▪ High degree of visibility to meet or exceed goal of $3 billion of new end-to-end NPR in 2020 RevWorks/Cerner Partnership ▪ RevWorks acquisition complet
Slide 7: Digital Transformation
Digital Transformation Patient Experience Platform (PX) ▪ With the acquisition of SCI, we now have comprehensive digital patient interface capabilities across the front office, inclusive of scheduling, contactless patient intake and financial clearance ▪ Recent signings for PX include Boston Childre
Slide 8: 2Q'20 Non-GAAP Results – Q/Q and Y/Y Comparison
2Q’20 Non-GAAP Results – Q/Q and Y/Y Comparison ($ in millions) 2Q’20 1Q’20 2Q’19 Key change driver(s) • Q/Q: Volume and incentive fee reduction due to COVID-19 Revenue $314.7 $320.5 $295.0 • Y/Y: New customer wins and organic growth at existing customers • Q/Q: Cost containment initiatives and lowe
Slide 9: Additional Commentary
Additional Commentary Net debt1 of $443.4 million as of 6/30/20, including restricted cash ▪ Up sequentially due to incremental borrowing to fund SCI acquisition Sufficient liquidity to withstand a wide range of scenarios ▪ Cash, revolver availability and expected proceeds from EMS divestiture equat
Slide 10: Appendix
Appendix 10
Slide 11: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures ▪ In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non-GAAP financial performance mea
Slide 12: Reconciliation of GAAP to Non-GAAP Financials
Reconciliation of GAAP to Non-GAAP Financials $ in millions Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA Three Months Ended Three Months Ended June 30, March 31, 2020 2019 2020 Net income (loss) $ 15.1 $ (5.2) $ 18.2 Net interest expense 4.8 9.9 3.8 Income tax provision (bene
Slide 13: Reconciliation of GAAP to Non-GAAP Financials
Reconciliation of GAAP to Non-GAAP Financials $ in millions Reconciliation of GAAP Operating Income Guidance to Non-GAAP Adjusted EBITDA Guidance 2020 GAAP Operating Income Guidance $90-110 Plus: Depreciation and amortization expense $65-75 Share-based compensation expense $20-25 Strategic initiativ